Main page content

Displaying results 1 - 10 of 21
Publication ID: PEP24-07-019
Published:

Drug Abuse Warning Network (DAWN): ED Visits Involving Alcohol Short Report presents the following data from January 2021-September 2023 (1) national estimates and characteristics of alcohol-related ED visits (2) demographics of alcohol-related ED visits (3) percent of ED visits related to alcohol and at least one other substance.

Publication ID: PEP23-07-00-001
Published:

The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.

Publication ID: PEP21-06-01-002
Published:

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

Publication ID: PEP21-06-02-002
Published:

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

Publication ID: PEP21-03-10-009
Published:

This user guide provides a digestible overview of the Report to Congress for prevention professionals, state and local agencies, and community-based organizations.

Publication ID: PEP21-02-01-003
Published:

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Publication ID: PEP21-02-01-002
Published:

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

Publication ID: PEP20-03-10-001
Published:

This guide highlights steps taken by the Frostburg State University community to reduce underage and high-risk drinking among the student population and discusses how these strategies were implemented.

Publication ID: PEP20-03-10-002
Published:

This guide shows how HBCUs, as well as other institutions that primarily serve students from a distinct background, region, or culture, can create prevention strategies to meet the unique needs of those students.

Publication ID: PEP21-PL-Guide-5
Published:

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.

Displaying 1 - 10 out of 21